Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.

Related Articles

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.

Trials. 2016 Nov 25;17(1):563

Authors: Bouattour M, Soubrane O, de Gramont A, Faivre S

Abstract
Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT00692770 . Registered 5 June 2008. This study has been completed.

PMID: 27887632 [PubMed - indexed for MEDLINE]

http://ift.tt/2CAfK4X